Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 2019 Jul 2;129(8):3464. doi: 10.1172/JCI131245

Targeting ceramide synthase 6–dependent metastasis-prone phenotype in lung cancer cells

Motoshi Suzuki, Ke Cao, Seiichi Kato, Yuji Komizu, Naoki Mizutani, Kouji Tanaka, Chinatsu Arima, Mei Chee Tai, Kiyoshi Yanagisawa, Norie Togawa, Takahiro Shiraishi, Noriyasu Usami, Tetsuo Taniguchi, Takayuki Fukui, Kohei Yokoi, Keiko Wakahara, Yoshinori Hasegawa, Yukiko Mizutani, Yasuyuki Igarashi, Jin-ichi Inokuchi, Soichiro Iwaki, Satoshi Fujii, Akira Satou, Yoko Matsumoto, Ryuichi Ueoka, Keiko Tamiya-Koizumi, Takashi Murate, Mitsuhiro Nakamura, Mamoru Kyogashima, Takashi Takahashi
PMCID: PMC6668672  PMID: 31264973

Original citation: J Clin Invest. 2016;126(1):254–265. https://doi.org/10.1172/JCI79775

Citation for this expression of concern: J Clin Invest. 2019;129(8):3464 https://doi.org/10.1172/JCI131245

The corresponding author recently notified the JCI that the patient data presented in Figure 1B were not correct. Analysis of the correct patient data set does not show a significant difference in CERS6 expression in human lung adenocarcinomas with positive invasive growth (definite) compared with those with negligible invasive growth or without invasive growth (focal/none). The Editors have requested an institutional investigation into this matter, and we will inform our readers of the outcome when the investigation is complete.

Version 1. 07/02/2019

Electronic publication

Version 2. 08/01/2019

Print issue publication

Footnotes

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES